

Kind invitation to the lecture

Novel Therapeutic Targets in T-ALL

Prof. Dr. Daniel Herranz

Rutgers Cancer Institute of New Jersey



Friday 29th September
10:30 am – 11:45 am



Seminar room MRB2
Campus Heymans/UZ
Ground floor

About

Dr Herranz studied Pharmacy in the University of Madrid (Spain) and obtained his PhD at the Spanish National Cancer Centre under the supervision of Dr. Manuel Serrano. During this period, he focused on the molecular and genetic characterization of Sirt1 in metabolism and cancer. After completing his PhD training, Dr Herranz joined the lab of Dr. Adolfo Ferrando at Colombia University. There, he led a study on NOTCH1-bound enhancers resulting in the identification of N-Me, which was published in Nature Medicine. In 2017, Dr. Herranz started his independent laboratory at Rutgers Cancer Institute and has since published several high-impact papers in Blood Cancer Discovery and Blood.

Hosted by Prof. Dr. Tom Taghon